Pharmacological female contraception: An overview of past and future use

Expert Opinion on Investigational Drugs

Volumn 14, Issue 4, 2005, Pages 449-456

  Economidis, Megan A ^a   Mishell Jr , Daniel R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Contraception; Contraceptive vaginal ring; Injectable contraception; IUD; Oral contraceptive pill; Subdermal contraceptive implant; Transdermal contraceptive system

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; DROSPIRENONE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; FOLLITROPIN; GESTAGEN; GONADORELIN; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MESTRANOL; NANDROLONE; NORETHISTERONE; NORETYNODREL; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PLACEBO; SILASTIC;

ACNE; AMENORRHEA; BODY WEIGHT DISORDER; BREAKTHROUGH BLEEDING; BREAST DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; FOLLITROPIN RELEASE; FRACTURE; GONADORELIN RELEASE; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INJECTION PAIN; INJECTION SITE REACTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LEGAL ASPECT; LUTEINIZING HORMONE RELEASE; META ANALYSIS; NAUSEA; NERVOUSNESS; OSTEOPOROSIS; PATIENT COMPLIANCE; POLITICAL SYSTEM; PREGNANCY RATE; REVIEW; SEBORRHEA; SIDE EFFECT; SKIN ATROPHY; SKIN DISEASE; SKIN GRANULOMA; SOCIAL ASPECT; SPOTTING; VAGINA RING; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CONTRACEPTION; CONTRACEPTIVES, ORAL, HORMONAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTRAUTERINE DEVICES;

EID: 19044383958     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.4.449     Document Type: Review

References (35)

1. PICCININI LJ, MOSHER WD: Trends in contraception use in the United States 1982-1995. Fam. Plan. Perspect. (1998) 30:4-10.
2. Unplanned pregnancy and abortion: options for the future. In: Sharing Responsibility: Women, Society, and Abortion Worldwide. Allan Guttmacher Institute, NY, USA (1999):42.
3. MISHELL DR Jr, THORNEYCROFT IH, NAKAMURA RM et al.: Serum estradiol in women ingesting combination oral contraceptive steroids. Am. J. Obstet. Gynecol. (1972) 129:923.
4. MISHELL DR Jr, KLETSKY OA, BREENER PR et al.: The effect of contraceptive steroids on hypothalamic-pituitary function. Am. J. Obstet. Gynecol. (1978) 130:817.
5. SCOTT JA, BRENNER PF, KLETZKY OA et al.: Factors affecting pituitary gonadotropin in users of oral contraceptive steroids. Am. J. Obstet. Gynecol. (1978) 130:881.
6. SCOTT JA, KLETZKY OA, BRENNER PF et al.: Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function. Fertil. Steril. (1978) 30:141.
7. PARSEY KS, PONG A: An open-label multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception (2000) 61:105-111.
8. HUBER J, FOIDART JM, WUTTKE W et al.: Efficacy and tolerability of a monophasic oral contraceptive containing ethinyl estradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care (2000) 5:25-34.
9. BORENSTEIN J, YU HT, WADE S: Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J. Reprod. Med. (2003) 48(2):79.
10. APTER D, BORSOS A, BAUMGARTNER W et al.: Effect of an oral contraceptive containing drospirenone and ethinyl estradiol on general well-being and fluid-related symptoms. Eur. J. Contracep. Reprod. Health Care (2003) 8(1):37.
11. ANDERSON FD, HAIT H. Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception (2003) 68:89-96.
12. ABRAMS LS, SKEE DM, NATARAJAN J et al.: Pharmacokinetic overview of Ortho Evra/Evra. Fertil. Steril. (2002) 77(Suppl. 2):S3.
13. ZIEMAN M, GUILLEBAUD J, WEISBERG E et al.: Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil. Steril. (2002) 77(Suppl. 2):S13.
14. AUDET MC, MOREAU M, KILTUN WD et al.: Evaluation of contraceptive efficacy and cycle control of transdsermal contraceptive patch versus an oral contraceptive: a randomized controlled trial. J. Am. Med. Asssn. (2001) 285:2347.
15. ZACUR HA, HEDON B, MANSOUR D et al.: Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil. Steril. (2002) 77(Suppl. 2):S32.
16. ABRAMS LS, SKEE DM, NATARAJAN J et al.: Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J. Clin. Pharm. (2001) 41:1301.
17. ROUMEN FJ, APTER D, MULDERS TM et al.: Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Human Reprod. (2001) 16:469.
18. TIMMER CH, MULDERS TM: Pharmacokinetics of etonogestrel and ethinyl estradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinetics (2000) 39:233.
19. TITIA M, MULDERS TM, DIEBEN TM: Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil. Steril. (2001) 75:865.
20. BJARNADOTTIR RI, TUPPURAINEN M, KILLICK SR: Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am. J. Obstet. Gynecol. (2002) 186:389.
21. JAIN J, DUTTON C, NICOSIA A et al.: Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception (2004) 70:11.
22. JAIN J, JAKIMIUK AJ, BRODE FR et al.: Contraceptive efficacy and safety of DMPA-SC. Contraception (2004) 70:269.
23. HUBER J. Pharmacokinetics of Implanon. Contraception (1998) 58:85S.
24. MASCARENHAS L. Insertion and removal of Implanon. Contraception (1998) 58:79S.
25. CROXATTO HB, MAKARAINEN L: The pharmacodynamics and efficacy of Implanon. Contraception (1998) 58:91S.
26. EDWARDS JE, MOORE A: Implanon. A review of clinical studies. Br. J. Fam. Plann. (1999) 24(Suppl. 4):3.
27. BEERTHUIZEN R, VAN BEEK A, MASSAI R et al.: Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum. Reprod. (2000) 15:118.
28. AFFANDI B: An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. Contraception (1998) 58:99S.
29. ZHENG SR, ZHENG HM, QIAN SZ et al.: A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception (1999) 60:1.
30. BARDIN W, MISHELL DR (Eds): Proceedings from the Fourth International Conference on IUDs, Newton, Butterworth-Heinemann, London, UK (1994):248-271.
31. ANDERSON K, RYBO G: Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br. J. Obstet. Gynaeol. (1990) 97:690.
32. LUUKKAINEN T, PAKARINEN P, TOIVONEN J: Progestin-releasing intrauterine systems. Semin. Reprod. Med. (2001) 19(4):35.
33. MISHELL DR Jr, BELL JH, GOOD RG et al.: The intrauterine device: a bacteriologic study of the endometrial cavity. Am. J. Obstet. Gynecol. (1966) 96:119.
34. FARLEY TM, ROSENBERG MJ, ROWE PJ et al.: Intrauterine devices and pelvic inflammatory disease: An international perspective. Lancet (1992) 339:785.
35. VESSEY MP, LAWLESS M, McPHERSON K et al.: Fertility after stopping use of intrauterine contraceptive device. Br. Med. J. (1983) 286:106.